Table 2.
Summary of the platforms, dosing schedule, no. of doses and route of administration of candidate vaccines in the clinical trials [2].
| Platforms of the Candidate Vaccines | |||
|---|---|---|---|
| Platform | Candidate Vaccine (No. and %) | ||
| PS | Protein subunit | 20 | 31% |
| VVnr | Viral Vector (non-replicating) | 10 | 16% |
| DNA | DNA | 8 | 13% |
| IV | Inactivated Virus | 9 | 14% |
| RNA | RNA | 7 | 11% |
| VVr | Viral Vector (replicating) | 4 | 6% |
| VLP | Virus Like Particle | 2 | 3% |
| VVr + APC | VVr + Antigen Presenting Cell | 2 | 3% |
| LAV | Live Attenuated Virus | 1 | 2% |
| VVnr + APC | VVnr + Antigen Presenting Cell | 1 | 2% |
| Dosing Schedule and No. of Doses of Candidate Vaccines | |||
| No. of Doses | Dosing Schedule | Candidate Vaccine (No. and %) | |
| 1 dose | Day 0 | 12 | 19% |
| 2 doses | Day 0,14 (5), Day 0, 21 (16), Day 0, 28 (17) | 38 | 59% |
| 3 doses | Day 0, 28, 56 | 1 | 2% |
| No Data | NA | 13 | 20% |
| Route of Administration of Candidate Vaccines | |||
| Route of Administration | Candidate Vaccine (No. and %) | ||
| PO | Oral | 3 | 5% |
| SC | Subcutaneous | 2 | 3% |
| ID | Intradermal | 3 | 5% |
| IM | Intramuscular | 48 | 75% |
| No Data | 8 | 13% | |